| Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy, V Sarangi, ... The Lancet Infectious Diseases 21 (5), 637-646, 2021 | 453 | 2021 |
| Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a … R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru, S Prasad, D Das, ... The Lancet Infectious Diseases 21 (7), 950-961, 2021 | 359 | 2021 |
| Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial R Ella, S Reddy, W Blackwelder, V Potdar, P Yadav, V Sarangi, VK Aileni, ... The Lancet 398 (10317), 2173-2184, 2021 | 354 | 2021 |
| Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune … R Ella, S Reddy, H Jogdand, V Sarangi, B Ganneru, S Prasad, D Das, ... medRxiv, 2020.12. 21.20248643, 2020 | 48 | 2020 |
| Awareness and Disposal Practices of Unused and Expired Medication Among Health Care Professionals and Students in A Tertiary Care Teaching Hospital. RRJ Raja S, Mohapatra S, Kalaiselvi A Biomedical and Pharmacolgy Journal 11 (4), 2073-2078, 2018 | 38 | 2018 |
| A phase 1: safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152 R Ella, KM Vadrevu, H Jogdand, S Prasad, S Reddy, V Sarangi, ... MedRxiv, 2020.12. 11.20210419, 2020 | 27 | 2020 |
| Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants KM Vadrevu, B Ganneru, S Reddy, H Jogdand, D Raju, G Sapkal, ... Scientific reports 12 (1), 12038, 2022 | 26 | 2022 |
| Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS‐CoV‐2 vaccine 1 (BBV152): a, double‐blind, randomised, controlled phase 3 trial R Ella, S Reddy, W Blackwelder, V Potdar, P Yadav, V Sarangi, VK Aileni, ... MedRxiv, 2021 | 25 | 2021 |
| E cacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial R Ella, S Reddy, W Blackwelder, V Potdar, P Yadav, V Sarangi, VK Aileni, ... Lancet 398 (10317), 2173-84, 2021 | 19 | 2021 |
| Knowledge, attitude towards human papillomavirus and HPV vaccine among medical students of a tertiary care teaching hospital in India S Tripathy, S Mohapatra, M Muthulakshmi, R Rani Int J Reprod Contracept Obstet Gynecol 4 (6), 1771-4, 2015 | 17 | 2015 |
| Induction of ovulation with clomiphene citrate versus clomiphene with bromocriptine in PCOS patients with normal prolactin: a comparative study S Tripathy, S Mohapatra, M Muthulakshmi, A Chandrasekhar Journal of clinical and diagnostic research: JCDR 7 (11), 2541, 2013 | 13 | 2013 |
| Prescription patterns of hypolipidaemic drugs in a tertiary care teaching hospital of southern India S Raja, S MohapatRa, JS Kumar, RJ Rani Journal of Clinical and Diagnostic Research: JCDR 8 (4), HC01, 2014 | 12 | 2014 |
| Pharmacological consideration of COVID-19 infection and vaccines in pregnancy S Mohapatra, P Ananda, S Tripathy Journal of the Chinese Medical Association 85 (5), 537-542, 2022 | 8 | 2022 |
| Prescribing pattern of antimicrobial agents in pediatrics department of a teaching hospital S Mohapatra, S Tripathy, C Balaji, RJ Rani, P Sekar International Journal of basic and clinical pharmacology 4 (4), 753-756, 2015 | 8 | 2015 |
| ANTIOXIDANT PROPERTIES OF ALOE VERA IN STREPTOZOTOCIN INDUCED DIABETIC RATS ST SATYAJIT MOHAPATRA, SUPRIYA PRADHAN, BANDANA RATH International Journal of Pharma and Bio Sciences 4 (3), 187-191, 2013 | 8 | 2013 |
| Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial KM Vadrevu, B Ganneru, S Reddy, H Jogdand, D Raju, U Praturi, ... MedRxiv, 2022.01. 05.22268777, 2022 | 7 | 2022 |
| Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial M Raches Ella, S Kanungo, S Rai, P Reddy, S Verma, C Singh, S Redkar, ... | 7 | 2021 |
| Screening of cetirizine for analgesic activity in mice M Priya, NV Sathya, M Satyajit, RR Jamuna Int J Basic Clin Pharmacol 2 (2), 187-92, 2013 | 7 | 2013 |
| Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: A phase 1, double-blind, randomised control trial R Ella, KM Vadrevu, H Jogdand, SD Prasad, S Reddy, V Sarangi, ... | 5 | 2020 |
| Efficacy of a bivalent (D614+ B. 1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo … GH Dayan, N Rouphael, SR Walsh, A Chen, N Grunenberg, M Allen, ... The Lancet Respiratory Medicine 11 (11), 975-990, 2023 | 4 | 2023 |
